Could a common heartburn drug shield lung cancer patients from radiation side effects?
NCT ID NCT06120803
First seen Aug 14, 2026 · Last updated Aug 14, 2026
Summary
This phase II trial tests whether esomeprazole, a common acid-reducing drug, can lower the chance of severe esophagitis (inflammation of the food pipe) in people with stage III non-small cell lung cancer receiving radiation therapy. Participants take 40 mg of esomeprazole daily during radiation and for two weeks after. The study measures how many patients develop grade 2 or higher esophagitis, using both doctor and patient reports.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- esomeprazole 40 mg once daily during and after thoracic radiation therapy
- What this could lead to
- If effective, esomeprazole could become a simple, low-cost way to prevent painful swallowing and chest discomfort during radiation for lung cancer, improving quality of life.
- What could go wrong
- This is a small, single-arm phase II trial, so results may not be definitive. Esomeprazole may not reduce esophagitis, and it carries rare risks like headache, diarrhea, or long-term effects with extended use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rush University Medical Center
RECRUITINGChicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.